Tiziana Life Sciences (TLSA) Cash & Equivalents (2017 - 2025)

Tiziana Life Sciences (TLSA) has reported Cash & Equivalents for 9 consecutive years, with $4.0 million the latest figure, recorded in Q4 2025.

• Quarterly Cash & Equivalents rose 7.68% year-over-year to $4.0 million in Q4 2025, while the trailing twelve-month figure through Dec 2025 was $4.0 million (up 7.68% YoY) and the FY2025 annual result came in at $4.0 million, up 7.68% from the prior year.
• Cash & Equivalents declined to $4.0 million in Q4 2025 per TLSA's latest filing, from $7.3 million in the prior quarter.
• Over the last five years, Cash & Equivalents for TLSA reached as high as $53.3 million in Q2 2021 and fell as low as $1.1 million in Q2 2024.
• A 5-year average of $16.4 million and a median of $6.9 million in 2023 frame the typical range for Cash & Equivalents.
• Annual changes were most pronounced in 2023 — Cash & Equivalents sank 93.47% — and 2025, when it soared 541.68%.
• Year by year, Cash & Equivalents stood at $42.2 million in 2021, then sank by 57.04% to $18.1 million in 2022, then plunged by 93.47% to $1.2 million in 2023, then soared by 214.79% to $3.7 million in 2024, then advanced by 7.68% to $4.0 million in 2025.
• According to Business Quant data, Cash & Equivalents over the past three periods registered $4.0 million, $7.3 million, and $3.7 million for Q4 2025, Q2 2025, and Q4 2024 respectively.